Le et al. reported a phase II clinical trial of progressive metastatic carcinoma with or without MMR deficiency, and revealed significantly increased somatic mutations per tumor in the MMR–deficient tumors compared with the MMR-proficient tumors (mean, 1782 vs. 73). This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.